Pfenex, US Government Extends Anthrax Vaccine Pact
Pfenex modifies its contract with US government for Anthrax vaccine.
Pfenex, a biotechnology company offering recombinant protein expression, and the Department of Health and Human Services through the Biomedical Advanced Research and Development Authority (BARDA), have modified their prime contract and exercised an option associated with their existing contractual relationship that began in July 2010. This modified agreement extends the prime contract and increases the funding to support the development of a recombinant protective antigen (rPA)-based anthrax vaccine based on rPA produced in the company’s platform technology, Pfēnex Expression Technology. The increase in funding of approximately $8.0 million brings the total funding available to approximately $23.9 million over the course of the contract if all options are exercised.
During the contract’s base period, Pfenex demonstrated that a strongly immunogenic, stable, and protective form of rPA could be expressed and recovered from the fermentation of a strain of P. fluorescens engineered to produce rPA. The exercise of this option allows for the completion of preclinical studies, implementation of analytical methods, and cGMP manufacturing.
Source: Pfenex
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
